Crinetics Pharmaceuticals Inc

{ "date": [ "202612", "202712", "202812", "202912", "203012" ], "revenue_estimate": [ 68.51, 177.45, 417.99, 916.36, 1558.8 ], "ebit_estimate": [ -548.82, -486.75, -284.21, 84.36, 594.35 ], "ebitda_estimate": [ -510.6, -437.86, -237.84, null, null ], "net_income_estimate": [ -508.87, -447.31, -266.96, 150.06, 620.21 ], "per_share_eps_estimate": [ -4.83, -4.34, -2.53, 0.98, 4.54 ], "eps_nri_estimate": [ -4.81, -4.2, -2.4, 0.98, 4.54 ], "dividend_estimate": [ null, null, null, null, null ], "book_value_per_share_estimate": [ 9.5, 9.84, 9.86, null, null ], "pretax_income_estimate": [ -499.83, -449.53, -246.23, 141.34, 667.52 ], "operating_cash_flow_per_share_estimate": [ -4.28, -3.45, -1.96, null, null ], "roa_estimate": [ -61.1, -77.4, null, null, null ], "roe_estimate": [ -47.48, -36.95, -17.82, null, null ], "gross_margin_estimate": [ 91.99, 89.67, 90.33, 92, 92.5 ], "operating_cash_flow_estimate": [ -445.54, -359.14, -204.03, null, null ], "pettm_estimate": [ 0, 0, 0, 85.64, 18.43 ], "long_term_growth_rate_mean": 20.63, "long_term_revenue_growth_rate_mean": "264.59", "future_per_share_eps_estimate_growth": 19.09, "future_eps_nri_estimate_growth": 20.63, "future_revenue_estimate_growth": 264.59, "future_ebit_estimate_growth": 17.42, "future_ebitda_estimate_growth": 21.8, "future_dividend_estimate_growth": null, "future_net_income_estimate_growth": 16.44, "future_pretax_income_estimate_growth": 18.24, "future_book_value_per_share_estimate_growth": null, "future_roa_estimate_growth": null, "future_roe_estimate_growth": 23.58, "future_gross_margin_estimate_growth": null, "future_operating_cash_flow_per_share_estimate_growth": 21.1 }

{ "date": [ "202606", "202609", "202612", "202703", "202706", "202709", "202712", "202803" ], "revenue_estimate": [ 14.84, 18.97, 24.15, 27.22, 40.31, 49.49, 60.45, null ], "ebit_estimate": [ -136.19, -135.94, -133.44, -124.37, -120.24, -115.73, -110.6, null ], "ebitda_estimate": [ -112.67, -118.32, -119.68, -111.3, null, null, null, null ], "net_income_estimate": [ -126.84, -127.45, -128.36, -118, -110.51, -105.6, -100.04, null ], "per_share_eps_estimate": [ -1.24, -1.23, -1.21, -1.16, -1.11, -1.07, -1.02, null ], "eps_nri_estimate": [ -1.24, -1.23, -1.19, -1.14, -1.06, -1.02, -0.96, -1.05 ], "dividend_estimate": [ null, null, null, null, null, null, null, null ], "book_value_per_share_estimate": [ null, null, null, null, null, null, null, null ], "pretax_income_estimate": [ -128.39, -125.71, -125.18, -119.08, -112.61, -108.17, -103.08, null ], "operating_cash_flow_per_share_estimate": [ -1.04, -1.06, -1.15, -1.02, -0.96, -0.9, -0.81, null ], "roa_estimate": [ null, null, null, null, null, null, null, null ], "roe_estimate": [ null, null, null, null, null, null, null, null ], "gross_margin_estimate": [ 91.33, 91.33, 90.67, 90.5, 90.5, 90.5, 90.5, null ], "operating_cash_flow_estimate": [ -108.26, -110.35, -119.71, -106.18, -99.94, -93.69, -84.32, null ], "pettm_estimate": [ 0, 0, 0, 0, null, null, null, null ], "long_term_growth_rate_mean": 20.63, "long_term_revenue_growth_rate_mean": "264.59", "future_per_share_eps_estimate_growth": 19.09, "future_eps_nri_estimate_growth": 20.63, "future_revenue_estimate_growth": 264.59, "future_ebit_estimate_growth": 17.42, "future_ebitda_estimate_growth": 21.8, "future_dividend_estimate_growth": null, "future_net_income_estimate_growth": 16.44, "future_pretax_income_estimate_growth": 18.24, "future_book_value_per_share_estimate_growth": null, "future_roa_estimate_growth": null, "future_roe_estimate_growth": 23.58, "future_gross_margin_estimate_growth": null, "future_operating_cash_flow_per_share_estimate_growth": 21.1 }